Efficacy of Letermovir in Preventing Cytomegalovirus (CMV) Infection in Lung Transplant Recipients vs. Valganciclovir. — LETERCOR

Infections, Cytomegalovirus Clinical Trial

Official title:
Prospective Study to Assess the Efficacy of Letermovir Prophylaxis in Preventing CMV Infection in Lung Transplant Recipients Compared to a Retrospective Cohort Treated With Standard Valganciclovir Prophylaxis for 12 Months (LETERCOR Study)

Status Not yet recruiting

Clinical Trial Summary

The goal of this quasi-experimental multicenter before-after cohort study, phase II study is to evaluate the efficacy of 12-month letermovir prophylaxis in lung transplant recipients (D+/R-) compared to a historical cohort of lung transplant recipients (D+/R-) who received 12 months of valganciclovir prophylaxis to prevent CMV disease."

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06057194
Study type	Interventional
Source	Maimónides Biomedical Research Institute of Córdoba
Contact	Jose C Garrido Gracia, Ph.D
Phone	+34677906567
Email	josecarlos.garrido@imibic.org
Status	Not yet recruiting
Phase	Phase 2
Start date	October 2023
Completion date	April 2027

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01691820` - A Study in Adolescent Females to Explore Cytomegalovirus Infection	N/A
Completed	`NCT01357915` - Evaluation of the Long-term Persistence of GlaxoSmithKline (GSK) Biologicals' Candidate Cytomegalovirus (CMV) Vaccine	N/A
Completed	`NCT00435396` - Study to Evaluate Safety and Immunogenicity of the GSK Bio CMV Vaccine in CMV-seronegative Healthy Male Adult Subjects	Phase 1
Completed	`NCT01251744` - Study of the Transmission of Cytomegalovirus (CMV) Infection From Mother to Foetus	N/A